Workiva Unveils Intelligent Finance, GRC, and Sustainability to Accelerate AI Transformation for the Office of the CFO
9.9.2025 15:00:00 EEST | Business Wire | Press release
Workiva Inc. (NYSE: WK), the world’s leading AI-powered platform for transparency, accountability, and trust, announced today at Amplify a major expansion of its intelligent platform, introducing agentic AI, unified data automation, and a modernized controls experience for the Office of the CFO. The new capabilities allow finance, GRC, and sustainability teams to streamline complex workflows, proactively manage risk, and deliver insights with speed and confidence.
Economic volatility, evolving regulations, and increasing complexity have left CFOs and their teams burdened by manual processes and siloed systems. In fact, nearly two-thirds of global practitioners say they lack the high-quality data and governance needed to manage these challenges, a gap that leaves organizations vulnerable to costly errors and missed performance opportunities.
Workiva’s latest innovations were built to meet this moment, embedding agentic AI directly into critical workflows, automating processes that slow teams down, and giving them continuous, connected insights in a secure, auditable platform.
“CFOs are responsible for more than ever before, and that responsibility demands technology that is specialized, secure, and built for high-stakes decisions,” said David Haila, Chief Technology Officer, Workiva. “We’re delivering that support through agentic AI, connected data, and controls you can trust.”
Customers Accelerate Performance with AI
Companies including PwC, Cognizant, StoneX, McCormick, and Playa Hotels & Resorts are using Workiva’s AI-powered platform to accelerate reporting cycles, improve collaboration across functions, and strengthen confidence in both financial and non-financial data.
- “I’ve saved 40% of my time with Workiva and its AI capabilities. It’s a dramatic shift that’s allowed me to focus on more strategic, high-value projects. That extra time hasn’t just made my day easier; it’s really helped me broaden my impact and take on responsibilities I never would have imagined before,” said Deepa Rao, sustainability governance lead at Cognizant.
- “Workiva AI gives us the confidence to move fast without compromising on trust. We're accelerating narrative development, streamlining the population completeness and analytics process, and anticipating the questions that matter most to our executive team. It's transforming how we work and boosting our efficiency and effectiveness,” said Natalie Denman, audit supervisor at Flowserve.
- “Workiva AI gives us the confidence to move fast without compromising on trust. We’re accelerating SOX process narrative development, building continuous controls monitoring tools and anticipating the questions that matter most to our executive team,” said Stephen Cramer, head of internal audit for the Americas at StoneX.
Workiva AI: Agentic Intelligence for Finance, Risk, and Sustainability
Announced today, Workiva AI is redefining how finance, risk, and sustainability teams work by turning data complexity into AI-powered clarity. Workiva’s new capabilities are embedded directly into workflows through Intelligent Finance, Intelligent GRC, and Intelligent Sustainability.
With the power of Agentic AI, customers now gain access to shorter reporting cycles, faster research, and more time for strategic work. Workiva’s platform accelerates confident decision-making by connecting teams to trusted, governed data, helping leaders gain visibility, act confidently, and stay ahead in high-stakes environments.
See It In Action: To explore demos of Intelligent Finance, GRC, and Sustainability, visit the Workiva Demo Center.
About Workiva
Workiva Inc. (NYSE: WK) powers transparency, accountability, and trust. Finance, accounting, sustainability, risk, and audit teams from more than 6,400 organizations worldwide, including over 80% of FORTUNE® 1,000 companies, rely on Workiva for their mission-critical work. We transform how customers connect data, unify processes, and empower teams in a secure, audit-ready, AI-powered, collaborative platform. Learn more at workiva.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909985184/en/
Contacts
Media:
Bill Bode
Workiva Inc.
press@workiva.com
Investor:
Katie White
Workiva Inc.
investor@workiva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom